Clinical Trials Logo

Recurrent Digestive System Neuroendocrine Tumor G1 clinical trials

View clinical trials related to Recurrent Digestive System Neuroendocrine Tumor G1.

Filter by:
  • None
  • Page 1

NCT ID: NCT01841736 Active, not recruiting - Clinical trials for Lung Carcinoid Tumor

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Start date: June 21, 2013
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01548482 Completed - Clinical trials for Stage IV Renal Cell Cancer

Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Start date: March 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of trebananib and temsirolimus when given together in treating patients with solid tumors that are metastatic or cannot be removed by surgery. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trebananib with temsirolimus may be an effective treatment for solid tumors.

NCT ID: NCT01204476 Completed - Paraganglioma Clinical Trials

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of cixutumumab when given together with everolimus and octreotide acetate in treating patients with advanced low- or intermediate-grade neuroendocrine cancer. Monoclonal antibodies, such as cixutumumab, may find tumor cells and help carry tumor-killing substances to them. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Octreotide acetate may interfere with the growth of tumor cells and slow the growth of neuroendocrine cancer. Giving cixutumumab together with everolimus and octreotide acetate may be a better treatment for neuroendocrine cancer.

NCT ID: NCT01010126 Completed - Clinical trials for Recurrent Ovarian Carcinoma

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Start date: September 8, 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of cancer by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may kill more tumor cells.

NCT ID: NCT00454363 Completed - Clinical trials for Pancreatic Polypeptide Tumor

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.